Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Inclusion Criteria:

1. The subjects are not limited by gender, age from 18 to 70 years old;
2. Histopathologically confirmed non-keratinizing squamous cell carcinoma of the nasopharynx;
3. Locally advanced nasopharyngeal squamous cell carcinoma diagnosed as T4 or N3 stage according to AJCC 8th edition staging;
4. ECOG score 0-1;
5. without distant metastasis;
6. This treatment must be the first course of treatment, and has not received any anti-tumor treatment such as radiotherapy and chemotherapy, immune or biological therapy in the past.
7. The expected survival is expected to be no less than 6 months.
8. No contraindications to chemotherapy, immunotherapy and radiotherapy;

Exclusion Criteria:

1. Received any systemic anti-tumor therapy for target lesions in the past;
2. Previously experienced head and neck radiation therapy;
3. Those who have received any immunotherapy such as anti-PD-1/PD-L1 monoclonal antibody, anti-CTLA-4 monoclonal antibody in the past;
4. Subjects who have been vaccinated with anti-tumor vaccines or other drugs with immunomodulatory functions (such as interleukin-2, thymosin, lentinan, etc.) within 1 month before enrollment, or who will be vaccinated with live attenuated vaccines. subject;
5. Subjects who have used corticosteroids (\>10 mg/day prednisone or other equivalent hormones) or other immunosuppressive agents for systemic treatment within 1 month before enrollment. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy at therapeutic doses of prednisone ≤10 mg/day are permitted;
6. Patients with pleural effusion, pericardial effusion or ascites that need to be drained with clinical symptoms, or who have received serous cavity effusion drainage for the purpose of treatment within 2 weeks before enrollment;